Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
Guardant Health (GH) and ConcertAI have announced a collaboration to create the first multi-modal real-world data solution that integrates comprehensive patient electronic medical records with genomic and epigenomic tumor profiling information across cancer care. The partnership combines ConcertAI's database of 5.5M clinical records with Guardant's profiling data across 60+ tumor types.
The integrated platform will provide biopharmaceutical companies access to extensive data including methylation data from Guardant Infinity smart liquid biopsy platform, helping researchers better understand disease biology, identify drivers of tumor evolution, and study resistance mechanisms. The solution covers the entire cancer care spectrum, from monitoring residual disease in early-stage cancer to treatment selection in advanced cases.
This collaboration aims to accelerate cancer therapy research and development by providing unprecedented insights into patient cancer journeys and tumor interactions. Financial terms of the agreement were not disclosed.
Guardant Health (GH) e ConcertAI hanno annunciato una collaborazione per creare la prima soluzione di dati reali multi-modale che integra registri medici elettronici completi dei pazienti con informazioni sulla profilazione genomica ed epigenomica dei tumori in tutta l'assistenza oncologica. La partnership combina il database di 5,5 milioni di registri clinici di ConcertAI con i dati di profilazione di Guardant su oltre 60 tipi di tumori.
La piattaforma integrata fornirà alle aziende biofarmaceutiche l'accesso a dati estesi, inclusi i dati di metilazione provenienti dalla piattaforma di biopsia liquida intelligente Guardant Infinity, aiutando i ricercatori a comprendere meglio la biologia della malattia, identificare i fattori che guidano l'evoluzione del tumore e studiare i meccanismi di resistenza. La soluzione copre l'intero spettro dell'assistenza oncologica, dal monitoraggio della malattia residua nel cancro in stadio precoce alla selezione del trattamento nei casi avanzati.
Questa collaborazione mira ad accelerare la ricerca e lo sviluppo della terapia oncologica fornendo intuizioni senza precedenti sui percorsi dei pazienti affetti da cancro e sulle interazioni tra tumori. I termini finanziari dell'accordo non sono stati divulgati.
Guardant Health (GH) y ConcertAI han anunciado una colaboración para crear la primera solución de datos del mundo real multimodal que integra los registros médicos electrónicos completos de los pacientes con información sobre la perfilación genómica y epigenómica de los tumores en toda la atención del cáncer. La asociación combina la base de datos de 5.5 millones de registros clínicos de ConcertAI con los datos de perfilación de Guardant en más de 60 tipos de tumores.
La plataforma integrada proporcionará a las empresas biofarmacéuticas acceso a datos extensos, incluidos los datos de metilación de la plataforma de biopsia líquida inteligente Guardant Infinity, ayudando a los investigadores a comprender mejor la biología de la enfermedad, identificar los factores que impulsan la evolución del tumor y estudiar los mecanismos de resistencia. La solución abarca todo el espectro de atención del cáncer, desde el monitoreo de la enfermedad residual en cánceres en etapas tempranas hasta la selección de tratamientos en casos avanzados.
Esta colaboración tiene como objetivo acelerar la investigación y el desarrollo de terapias contra el cáncer al proporcionar perspectivas sin precedentes sobre los caminos del cáncer en los pacientes y las interacciones tumorales. Los términos financieros del acuerdo no fueron divulgados.
Guardant Health (GH)와 ConcertAI가 최초의 다중 모드 실제 데이터 솔루션을 만들기 위해 협력한다고 발표했습니다. 이 솔루션은 종양 치료에 대한 유전자 및 후성유전자 프로파일링 정보와 환자의 전자 의무 기록을 통합합니다. 파트너십은 ConcertAI의 550만 임상 기록 데이터베이스와 Guardant의 60개 이상의 종양 유형에 대한 프로파일링 데이터를 결합합니다.
통합 플랫폼은 생명 제약 회사에 Guardant Infinity 스마트 액체 생검 플랫폼의 메틸화 데이터를 포함한 방대한 데이터에 대한 접근을 제공하여 연구자들이 질병 생물학을 더 잘 이해하고 종양 진화를 유도하는 인자를 식별하며 저항 메커니즘을 연구하는 데 도움을 줍니다. 이 솔루션은 초기 단계 암의 잔여질환 모니터링부터 고급 사례의 치료 선택에 이르기까지 전체 암 치료 스펙트럼을 포괄합니다.
이 협력의 목표는 환자의 암 여정 및 종양 상호작용에 대한 전례 없는 통찰력을 제공함으로써 암 치료 연구 및 개발을 가속화하는 것입니다. 계약의 재정적 조건은 공개되지 않았습니다.
Guardant Health (GH) et ConcertAI ont annoncé une collaboration pour créer la première solution de données réelles multimodale qui intègre des dossiers médicaux électroniques complets des patients avec des informations sur le profilage tumoral génomique et épigénomique dans le cadre des soins oncologiques. Le partenariat combine la base de données de ConcertAI de 5,5 millions de dossiers cliniques avec les données de profilage de Guardant sur plus de 60 types de tumeurs.
La plateforme intégrée fournira aux entreprises biopharmaceutiques un accès à des données étendues, y compris des données de méthylation provenant de la plateforme de biopsie liquide intelligente Guardant Infinity, aidant les chercheurs à mieux comprendre la biologie de la maladie, à identifier les facteurs à l'origine de l'évolution tumorale et à étudier les mécanismes de résistance. La solution couvre l'ensemble du spectre des soins oncologiques, de la surveillance de la maladie résiduelle dans le cancer à un stade précoce à la sélection du traitement dans les cas avancés.
Cette collaboration vise à accélérer la recherche et le développement de thérapies contre le cancer en fournissant des informations sans précédent sur les parcours des patients atteints de cancer et les interactions tumorales. Les conditions financières de l'accord n'ont pas été divulguées.
Guardant Health (GH) und ConcertAI haben eine Zusammenarbeit angekündigt, um die erste multimodale Lösung für reale Daten zu schaffen, die umfassende elektronische Patientenakten mit Informationen zur genomischen und epigenomischen Tumorprofilierung in der Krebsversorgung integriert. Die Partnerschaft kombiniert die Datenbank von ConcertAI mit 5,5 Millionen klinischen Aufzeichnungen und die Profilierungsdaten von Guardant über 60 Tumorarten.
Die integrierte Plattform wird biopharmazeutischen Unternehmen Zugang zu umfangreichen Daten bieten, einschließlich Methylierungsdaten von der intelligenten Flüssigbiopsie-Plattform Guardant Infinity, die Forschern hilft, die Biologie der Krankheit besser zu verstehen, Treiber der Tumorevolution zu identifizieren und Resistenzmechanismen zu untersuchen. Die Lösung deckt das gesamte Spektrum der Krebsversorgung ab, vom Monitoring der Restkrankheit im frühen Krebsstadium bis zur Auswahl der Behandlung in fortgeschrittenen Fällen.
Diese Zusammenarbeit zielt darauf ab, die Forschung und Entwicklung von Krebstherapien zu beschleunigen, indem sie beispiellose Einblicke in die Krebsreise der Patienten und die Tumorinteraktionen bietet. Die finanziellen Bedingungen der Vereinbarung wurden nicht veröffentlicht.
- Creation of industry's first integrated clinical-genomic database combining 5.5M clinical records with extensive tumor profiling data
- Access to unique methylation data from Guardant Infinity platform, providing new research dimensions
- Potential to accelerate drug development and clinical trials through comprehensive data insights
- None.
Insights
This strategic collaboration marks a pivotal advancement in oncology research data infrastructure. The integration of ConcertAI's 5.5 million clinical records with Guardant's comprehensive genomic and methylation profiling creates an unprecedented dataset that significantly enhances our understanding of cancer progression and treatment response patterns.
The inclusion of methylation data from Guardant Infinity's liquid biopsy platform is particularly groundbreaking. Methylation patterns serve as important epigenetic markers that can reveal how environmental factors and treatments influence gene expression, potentially uncovering new therapeutic targets and resistance mechanisms that genomic data alone cannot identify.
The AI-powered analytics capabilities will enable complex pattern recognition across this multi-modal dataset, potentially identifying previously unknown correlations between clinical outcomes, genomic profiles and epigenetic modifications. This could dramatically accelerate drug development timelines and improve clinical trial design efficiency.
The partnership represents a significant leap forward in precision oncology research. By combining comprehensive clinical data with longitudinal molecular profiling across 60+ tumor types, researchers can now track cancer evolution and treatment resistance in unprecedented detail. This is particularly valuable for understanding how cancers develop resistance to existing therapies.
The platform's ability to monitor disease across all stages - from early detection through advanced treatment - provides a complete view of cancer progression that has been largely unavailable until now. This continuous monitoring capability, coupled with methylation data, could revolutionize our understanding of tumor evolution and help identify optimal treatment windows for new therapeutic approaches.
For Guardant Health investors, this collaboration significantly strengthens the company's competitive position in the precision oncology market. The partnership creates a unique commercial offering that could generate substantial recurring revenue through pharmaceutical company subscriptions and research collaborations.
The deal enhances Guardant's market position by combining their advanced liquid biopsy technology with ConcertAI's extensive clinical database and AI capabilities. This integrated platform could become the gold standard for oncology drug development, potentially leading to increased adoption of Guardant's testing services and expanding their market share in the precision oncology space.
While financial terms weren't disclosed, this type of data-as-a-service model typically generates high-margin recurring revenue. The collaboration could accelerate Guardant's path to profitability by creating a new revenue stream separate from their core diagnostic business.
- Collaboration enables insights from ConcertAI national database of 5.5M clinical records and Guardant profiling data across 60+ tumor types
- Longitudinal DNA methylation measurements and comprehensive genomic profiling allow deeper insights into intrinsic and acquired resistance mechanisms
An individual patient’s cancer is complex, with response to medicines being determined by multiple factors, including specific driver mutations from the cancer, previous therapies and acquired resistance to those therapies. The creation of a joint RWD solution provides critical clinical context to an extensive database of solid tumor cancer patients with multiple liquid biopsies. This allows biopharma collaborators to better interpret disease biology and identify drivers and timing of tumor evolution as well as intrinsic and acquired resistance mechanisms. These are critical insights with causal associations that can guide the design of clinical trials and effective therapeutics. Through this collaboration, biopharmaceutical company partners can now leverage the joint dataset, combined analytics capability, AI SaaS solutions and precision oncology footprint of ConcertAI and Guardant Health.
“Realizing the potential of precision medicine requires a comprehensive, multi-dimensional understanding of the tumor, the clinical environment and the patient’s response to therapy,” said Helmy Eltoukhy, Guardant Health co-CEO. “This partnership between Guardant and ConcertAI gives evidence and outcomes researchers access to extensive, robust data and AI-based modeling that can provide unprecedented insight into a patient’s cancer journey, including a tumor’s complex systemic interactions, to help them accelerate the development of much-needed cancer therapies. It represents another milestone in Guardant’s mission to conquer cancer with data.”
The integrated data offering will be unique in the industry in that it will include methylation data from biomarker tests run on the Guardant Infinity smart liquid biopsy platform, which includes an extensive methylome panel that helps identify the unique methylation pattern that each tumor comprises. This provides an important new dimension of research insights that has been largely unexplored in clinical development to date. The dataset will also be unique in that it includes genomic profiling data across the continuum of cancer care, from monitoring for residual disease and recurrence in early-stage cancer to treatment selection and therapy response monitoring in advanced cancer.
“By integrating ConcertAI’s extensive clinical dataset and enterprise AI with the new data on tumor methylation patterns enabled by Guardant Health’s innovative sequencing technology, we can partner with biopharma researchers to enable novel approaches to cancer therapy discovery, clinical study design, and innovative models for clinical development,” said Jeff Elton, Ph.D., MBA, CEO of ConcertAI. “Providing biopharma collaborators with access to integrated data of this depth and scale will help accelerate new medicines needed by patients with cancer, especially those with few available targeted therapy options.”
Financial terms and other details of the agreement were not disclosed.
About Guardant Health Real-World Data
Guardant Health offers a large, multimodal clinical-genomic database that integrates information from next-generation sequencing, demographics, cancer diagnoses, treatment and procedures, and pharmacy prescription data for more than 60 solid tumor cancer types and over 450,000 unique patients across the cancer care continuum. The configurable real-world data (RWD) set can be used to elicit important insights into the drivers of therapy response and resistance across the treatment spectrum, and to support targeted therapy development, clinical trial optimization and post-marketing studies.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
About ConcertAI
ConcertAI is the leader in Generative AI technology and Real-World Evidence solutions for life sciences and healthcare. Our mission is to accelerate high confidence and actionable insights and outcomes for patients through multi-modal data, AI technologies, and scientific expertise in collaboration with leading biomedical innovators, health care providers, and medical societies. ConcertAI technologies are deployed in more than 1900 global healthcare provider settings and used by more than 45 leading biopharmaceutical innovators. ConcertAI operates Customer and Technology Development Centers in
Guardant Health Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250116840221/en/
Guardant Health Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Guardant Health Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035
ConcertAI Media Contact:
Treble
McKenzie Covell
concertai@treblepr.com
Source: Guardant Health, Inc.
FAQ
What is the purpose of Guardant Health's (GH) collaboration with ConcertAI?
How many clinical records and tumor types are covered in the GH-ConcertAI collaboration?
What unique data feature does the GH-ConcertAI partnership offer?
What range of cancer care does the GH-ConcertAI integrated platform cover?
